Hello Samwhatam,
Below you will find the results of my research regarding
platinum-based anti-cancer drugs.
?GPC Biotech AG (Frankfurt Stock Exchange: GPC) today announced that
it has signed an agreement with NeoTherapeutics, Inc. (NASDAQ: NEOTD)
granting GPC Biotech an exclusive worldwide license to satraplatin, an
orally-administered anti-cancer agent in late-stage clinical
development.?
http://www.lifescience-bavaria.de/portal/news_detail,6647,,10048,detail.html
Satraplatin - A third generation oral platinum drug
Initial Indication:
Hormone Refractory Prostate Cancer
Other Indications:
Solid tumors such as ovarian and lung cancers
Route of Administration: Oral
Mode of Action:
?Satraplatin binds to DNA of cancer cells and makes the cell incapable
of dividing to form new cancer cells, and eventually the cancer cell
dies. This causes the tumor to stop growing?.
Anti-Tumor Properties:
Anti-tumor activity in preclinical models is comparable to cisplatin
and carboplatin with less cross-resistance.
Satraplatin is the first orally administered platinum compound.
Satraplatin has been shown to enhance the antitumor activity of ionizing radiation
Status
?A Phase 3 study in Hormone Refractory Prostate Cancer began in
September, 2003. Satraplatin was given fast track review designation
by the FDA. Satraplatin is currently being co-developed by Spectrum
Pharmaceuticals and GPC Biotech, AG?
http://www.spectrumpharm.com/satraplatin.html
--------------------------------------------------------
Spectrum Pharmaceuticals
http://www.spectrumpharm.com/
Spectrum Pharmaceuticals, Inc.
157 Technology Drive
Irvine, CA 92618
BUS: (949) 788-6700
FAX: (949) 788-6706
http://www.spectrumpharm.com/hq.html
--------------------------------------------------------
GPC Biotech, AG
http://www.gpc-biotech.com/
GPC Biotech, AG
USA
http://www.gpc-biotech.com/site_usa/com_main.html
General information/Public Relations
info@gpc-biotech.com
?GPC Biotech says that it is to reveal a significant level of progress
in the development of its platinum-based cancer treatment at the 95th
Annual Meeting of the American Association for Cancer Research.
The firm says that it will chart progress at the Florida conference,
with its Satraplatin anticancer treatment performing well.
"We are pleased to present new data on several of our anticancer
programs at this important scientific meeting," said Marcel
Rozencweig, senior vice president, drug development. ?
http://www.platinum.matthey.com/media_room/1080561603.html
--------------------------------------------------------
?The new drug "is the first genuinely new platinum agent to enter
clinical trials in 30 years," says Farrell. He believes that it could
be on the market as early as 2004.
Code-named BBR3464, it belongs to a new class of platinum drugs, which
emerged from joint research by Farrell and Novuspharama SpA (formerly
Boehringer Mannheim Italia R&D) in Monza, Italy. By manipulating the
molecular structure, Farrell and his colleagues found a way to attack
DNA more effectively to keep cancer from spreading.
The new drug is significantly more potent than cisplatin, according to
Farrell. This means much lower doses can be given, he explained.
Primary funding for the research was from the American Cancer Society
and the National Institutes of Health. BBR3464 is licensed to Roche, a
research-oriented healthcare group, and is being developed under a
sublicense by Novuspharma. ?
http://www.globaltechnoscan.com/20thDec-26thDec/drug.htm
Merger of Novuspharma into CTI
Cell Therapeutics, Inc. (CTI) and Novuspharma S.p.A.
Complete Merger
http://www.cticseattle.com/inve_frame-merge.htm
Novel Platinum Compounds
?We have developed two potential drug candidates, BBR 3464 and BBR
3610, that are related to the platinum-based chemotherapy agent
Cisplatin. Cisplatin is one of the most widely used anti-cancer drugs
and acts by binding to DNA, thereby preventing its replication and
tumor cell division. However, while Cisplatin contains a single
platinum atom, our compounds consist of multiple platinum atoms held
together by linking molecules, allowing them to block DNA replication
more effectively. This was born out by preclinical studies, which
showed that BBR 3464 and BBR 3610 were far more effective than
Cisplatin, in a range of solid tumors. ?
http://www.cticseattle.com/prod_frame-novel.htm
Cell Therapeutics, Inc. (Europe)
(Formerly Novuspharma S.p.A.)
Via Ariosto, 23
20091 Bresso (MI) - Italy
T +39 02 61035.1
F +39 02 61035601
Cell Therapeutics (UK) Ltd
100 Pall Mall
London SW1Y 5HP, UK
T + 44 20 7664 8620
F + 44 20 7664 8621
Cell Therapeutics, Inc.
Corporate Headquarters
501 Elliott Avenue West, Suite 400
Seattle, WA 98119
(206) 282-7100
(800) 215-CELL (US)
http://www.cticseattle.com/contact.htm
--------------------------------------------------------
AMD473 - a platinum based anti-cancer drug
AnorMED Continues Clinical Development
?AMD473 has a broad spectrum of anti-tumor activity. It has been
evaluated in close to 500 patients and has a manageable toxicity
profile with no clinically significant kidney, nerve or hearing
toxicities. Preclinical results also demonstrate that AMD473 is orally
bioavailable.?
AnorMED
http://www.anormed.com/products/AMD473/index.cfm
?AMD473 is differentiated from the current platinum products in that
1) it has demonstrated activity in tumor types where these products
have limited activity; such as prostate cancer, and 2) it is orally
bioavailable.?
http://www.anormed.com/products/AMD473/ff_platinum.cfm
AnorMED Inc.
#200 - 20353 64th Avenue
Langley, British Columbia
Canada V2Y 1N5
info@anormed.com
T: 604.530.1057
F: 604.530.0976
NeoRx Corporation acquires worldwide rights to platinum-based anti-cancer agent
?NeoRx Corporation today announced that it has acquired from AnorMED
Inc. the worldwide exclusive rights, excluding Japan, to develop,
manufacture and commercialize AMD473, a platinum-based anti-cancer
agent. AMD473 has been administered to more than 500 cancer patients
in phase I and phase II clinical trials, demonstrating anti-cancer
activity in a wide range of tumors and a manageable safety profile.
NeoRx expects to initiate clinical studies of AMD473 in one or more
cancer indications in the second half of this year.?
News-Medical.Net: 5-Apr-2004
http://www.news-medical.net/?id=294
NeoRx Corporation
http://www.neorx.com/
NeoRx is developing a novel platinum-based therapeutic candidate, NX
473 (formerly AMD473), which it acquired from AnorMED Inc. in April
2004.
NeoRx expects to initiate clinical studies of NX 473 in one or more
cancer indications in the first half of 2005.
http://www.neorx.com/NRX473.htm
CONTACT INFORMATION
NeoRx Corporate Headquarters
300 Elliott Avenue West, Suite 500
Seattle, WA 98119
Telephone: 206-281-7001
Fax: 206-284-7112
NeoRx Manufacturing:
3100 Jim Christal Road
Denton TX 76207
Telephone: 940-484-9492
Fax: 940-484-0877
http://www.neorx.com/contact_info.htm
--------------------------------------------------------
AstraZeneca
?ZD0473 - an intravenous and potentially oral platinum-based cytotoxic
showing promise in the treatment of resistant disease in ovarian and nonsmall
cell lung cancer (NSCLC). Phase I studies are underway in Europe and
the USA using ZD0473 in combination with other cytotoxic agents.
Development for launch studies in ovarian and other tumours will start next
year, with regulatory submissions from 2001/2.?
http://www.astrazeneca.com/sites/7/imagebank/migratedpress/Rd-Presentation-0612.pdf
Worlwide locations
http://www.astrazeneca.com/node/addresses.aspx
--------------------------------------------------------
Callerio Foundation
?Platinum-based drugs (in particular cisplatin and oxaliplatin) have
marked cancer chemotherapy for the last 40 years. Beside their
indisputable activity, these drugs share with almost any other
chemotherapy drug a significant host toxicity and the possibility to
induce resistance in cancer cells. These two aspects have been and
still are the main targets for the development of new platinum-based
drugs capable of replacing cisplatin and its analogues with new
compounds more active and capable of circumventing tumour resistance
and/or exibiting a lower toxicity.?
The current approaches, in the preclinical development of new
platinum-based drugs, pursue these targets:
i) circumvent resistance;
ii) to include activity on refractary tumours;
iii) to improve pharmacokinetics, particularly in orally administrable drugs.
http://www.callerio.org/strat.htm
?The Callerio Foundation, a non-profit private organisation, begins
in1966 with biological research as its specific institutional target,
under the direction of the founder prof. Carlo Callerio. During its 34
years of activity this target has been focused more and more on the
research and the characterisation of new drugs active against tumours
and their metastases. The Foundation does not operate alone: aside of
the strict co-operation with the University of Trieste and several
research Institutions around the world, with the recent activation of
LINFA?
http://www.callerio.org/Foundat.htm
Callerio Foundation
Via Fleming 31 - 34127 Trieste ITALY
ph/fax +39 040 569933
http://www.callerio.org/Reach.htm
--------------------------------------------------------
Search criteria:
orally bioavailable platinum-based anti-cancer drugs
platinum-based cancer research
orally active platinum-based anti-cancer
Centerwatch Clinical Trials Listing Service
http://www.centerwatch.com/
Platinum Anti-Cancer Drugs
http://www.platinum.matthey.com/applications/medical.html
Johnson Matthey Pharmaceuticals
http://www.jmpharma.com/about.htm
I hope you find this information useful!
Best regards,
Bobbie7 |
